Stock Events

Stock Events

Xbrane Biopharma AB 

SEK10.60
11
-SEK0.10-0.93% 07:18 Today

Statistics

Day High
10.7
Day Low
10.65
52W High
38.1
52W Low
5.42
Volume
14
Avg. Volume
-
Mkt Cap
27.3B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17JulExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-1.16
3.85
8.87
13.89
Expected EPS
-0.53814951936
Actual EPS
N/A

Financials

-133.97%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
397.44MRevenue
-532.44MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow XBRANE.ST. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap138.44B
Pfizer is a global pharmaceutical company that competes with Xbrane in the development and commercialization of biosimilars, a key area for Xbrane.
Novartis
NVS
Mkt Cap296.54B
Novartis, through its generics division Sandoz, is a leading competitor in the biosimilars market, directly competing with Xbrane's offerings.
AMGEN
AMGN
Mkt Cap193.39B
Amgen has a strong presence in the biosimilars market, making it a direct competitor to Xbrane, especially in oncology and inflammatory disease treatments.
Bristol-Myers Squibb
BMY
Mkt Cap117.46B
Bristol Myers Squibb competes with Xbrane in the biopharmaceutical sector, particularly in the development of treatments for cancer and other diseases.
Merck
MRK
Mkt Cap317.77B
Merck is involved in the development of biosimilars and innovative treatments that compete with Xbrane's product pipeline.
Abbvie
ABBV
Mkt Cap447.62B
AbbVie, with its focus on biopharmaceuticals, including biosimilars, is a competitor to Xbrane, especially in areas like immunology.
Roche
RHHBY
Mkt Cap333.25B
Roche, through its Genentech division, competes in the biosimilars market, particularly in oncology, a key focus area for Xbrane.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap38.67B
Teva Pharmaceutical Industries is a global leader in generic and specialty medicines, including biosimilars, competing with Xbrane in multiple markets.
Biogen
BIIB
Mkt Cap31.89B
Biogen focuses on advanced biologics and biosimilars, making it a competitor to Xbrane, especially in neurology and autoimmune diseases.
Sanofi
SNY
Mkt Cap102.81B
Sanofi competes with Xbrane in the biosimilars and biopharmaceutical market, with a broad portfolio that includes treatments for various diseases.

About

Xbrane Biopharma AB (publ), a biotechnology company, engages in the development, manufacture, and sale of biosimilars. It offers Ximluci, a ranibizumab biosimilar used for the treatment of various eye diseases, including wet form of age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. The company also develops its pre-clinical phase products, such as Xdivane, a cell death 1 protein (PD1) inhibitor nivolumab biosimilar, indicated for melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane, a daratumumab biosimilar targeting CD38 for the treatment of multiple myeloma. The company has a strategic partnership with JOINN Biologics US Inc. to provide customized development services for Xdarzane, Xbrane´s biosimilar candidate referencing Darzalex. The company was incorporated in 2008 and is headquartered in Solna, Sweden.
Show more...
CEO
Mr. Martin Amark
Employees
28
Country
Sweden
ISIN
SE0026598583

Listings

STU
DE
7XB0.STU
MU
DE
7XB0.MU
F
DE
7XB0.F
ST
SE
XBRANE.ST

0 Comments

Share your thoughts

FAQ

What is Xbrane Biopharma AB stock price today?▼
The current price of XBRANE.ST is SEK10.60 SEK — it has decreased by -0.93% in the past 24 hours. Watch Xbrane Biopharma AB stock price performance more closely on the chart.
What is Xbrane Biopharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xbrane Biopharma AB stocks are traded under the ticker XBRANE.ST.
Is Xbrane Biopharma AB stock price growing?▼
XBRANE.ST stock has fallen by -1.4% compared to the previous week, the month change is a +1.44% rise, over the last year Xbrane Biopharma AB has showed a -66.35% decrease.
What is Xbrane Biopharma AB market cap?▼
Today Xbrane Biopharma AB has the market capitalization of 27.3B
When is the next Xbrane Biopharma AB earnings date?▼
Xbrane Biopharma AB is going to release the next earnings report on July 17, 2026.
What were Xbrane Biopharma AB earnings last quarter?▼
XBRANE.ST earnings for the last quarter are -1.16 SEK per share, whereas the estimation was 1.58 SEK resulting in a -173.75% surprise. The estimated earnings for the next quarter are N/A SEK per share.
What is Xbrane Biopharma AB revenue for the last year?▼
Xbrane Biopharma AB revenue for the last year amounts to 397.44M SEK.
What is Xbrane Biopharma AB net income for the last year?▼
XBRANE.ST net income for the last year is -532.44M SEK.
How many employees does Xbrane Biopharma AB have?▼
As of June 29, 2026, the company has 28 employees.
In which sector is Xbrane Biopharma AB located?▼
Xbrane Biopharma AB operates in the Health & Wellness sector.
When did Xbrane Biopharma AB complete a stock split?▼
Xbrane Biopharma AB has not had any recent stock splits.
Where is Xbrane Biopharma AB headquartered?▼
Xbrane Biopharma AB is headquartered in Solna, Sweden.